Image by pressfoto on Magnific
There is a recognisable moment in the life of a life sciences company. The science works, the funding round closed, headcount is climbing, and someone from quality asks who validated the system holding the batch records. The room goes quiet.
This is compliance debt, and it behaves exactly like technical debt: cheap to take on, expensive to repay, and it compounds silently until an inspection, an audit, or a partner’s due diligence forces settlement.
Why It Accumulates Rather Than Being Chosen
Nobody decides to defer compliance. It happens through a series of individually sensible decisions.
Early on, headcount goes to science because that is what the company is. Quality is a fractional consultant, or a scientist who has read the guidance. Systems get chosen for what they do rather than for whether their records will survive scrutiny, because at that stage there are no records worth scrutinising.
Then the company grows into a regulatory perimeter it did not previously occupy, and the systems and records created in the earlier phase are suddenly in scope. The debt was taken on years before anyone noticed the balance.
The Regulation Most Growth-Stage Teams Underestimate
The specific area where this bites hardest is electronic records.
The FDA’s guidance on Part 11, Electronic Records; Electronic Signatures sets out the agency’s thinking on the scope and application of 21 CFR Part 11, the rule governing when electronic records and signatures are treated as trustworthy and reliable equivalents to paper. Part 11 works alongside the other regulations, referred to as predicate rules, that establish what records must be kept, signed, and retained in the first place.
Two things about it consistently surprise growth-stage teams. First, it is technology-agnostic, so moving a record to a cloud service does not transfer responsibility for it. Second, the guidance describes a risk-based approach rather than a mandate to validate every system exhaustively, which is genuinely helpful but requires someone to have made and documented the risk judgments.
Nothing here is legal or regulatory advice. Any company assessing its own obligations should take advice from qualified regulatory counsel or a quality professional working in its specific area.
Across the sector, the same items show up repeatedly.
Undocumented decisions. The reasoning behind a specification, a deviation, or a supplier choice lived in someone’s head, and that person has left. Reconstructing it years later is expensive and sometimes impossible.
Unvalidated systems in regulated workflows. A spreadsheet, a lab instrument’s bundled software, or a SaaS tool that quietly became load-bearing for a regulated process.
Training records that do not reconcile. People trained on procedures that have since been revised, with no record of retraining, or trained on the wrong version.
Supplier oversight that stopped at the contract. Qualification performed once at onboarding and never revisited, with no periodic assessment.
Why Repayment Costs More Than Prevention
The multiple is unusually high in this sector, and the reason is retrospective reconstruction.
Prospective documentation is cheap because the people involved are present and the decisions are current. Retrospective documentation requires interviewing whoever remains, inferring rationale from artefacts, and in some cases repeating work whose evidence cannot be reconstructed at all.
A related cost is timing. Compliance debt tends to surface at the least convenient moment: during partner due diligence, ahead of a submission, or when an inspection is scheduled. That is precisely when your team has the least capacity, which is why remediation so often gets outsourced at premium rates.
For B2B readers the commercial angle is the more relevant one, and it is rarely discussed openly.
Quality findings surfaced during due diligence do not usually kill transactions. They reprice them. A partner or acquirer discovering material gaps will discount for remediation cost, build in holdbacks, or extend timelines while conditions are satisfied. All three come out of the seller’s side.
The same dynamic applies to commercial partnerships. A large pharma partner auditing a smaller company’s quality system before signing is assessing whether working with you creates exposure for them, and the answer shapes the terms rather than just the decision.
Building Versus Buying the Capability
The classic build-or-buy question applies here with an unusual wrinkle: the workload is lumpy.
A company preparing for a submission, remediating findings, or standing up a quality system needs substantially more capacity for a defined period than it needs afterwards. Hiring permanently for a peak leaves you overstaffed later, and hiring for the trough leaves the peak unresolved.
This is the structural reason specialist providers exist in this space. Firms offering SOKOL GxP Services and comparable consultancies are typically engaged for exactly that shape of work: a defined programme requiring experienced practitioners, without a permanent addition to headcount.
The judgment worth making early is which parts of quality are genuinely core to your organisation and should sit inside it, and which are episodic and better bought. Getting that wrong in either direction is expensive.
A short exercise that most companies can complete in a fortnight and rarely do.
List every system that touches a regulated record, including the spreadsheets. For each, record who owns it, whether it has been validated, and where the validation evidence lives. Note the gaps rather than fixing them yet.
Then check that your procedures reflect what people actually do, since divergence between written procedure and daily practice is among the most common findings and among the easiest to correct while it is still small.
Finally, assign an owner to each gap with a date. An inventory without owners becomes a document that gets shown to auditors as evidence that you knew and did nothing, which is worse than not having made the list.
The Argument to Make Internally
Framing this as regulatory obligation is why it loses to product work in planning meetings. It sounds like insurance.
The stronger framing is optionality. A company with a defensible quality system can enter a partnership discussion, respond to due diligence, or accelerate toward a submission without a six-month detour first. One carrying significant debt has those options priced or timed out of reach.
That is a commercial argument rather than a compliance one, and in most companies it is the only version that gets budget.
